Last update 06 Sep 2025

Chlorambucil

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
4-(p-bis(beta-chloroethyl)aminophenyl)butyric acid, 4-(p-bis(β-chloroethyl)aminophenyl)butyric acid, 4-[p-[bis(2-chloroethyl)amino]phenyl]butyric acid
+ [15]
Target
Action
inhibitors
Mechanism
DNA inhibitors(DNA inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC14H19Cl2NO2
InChIKeyJCKYGMPEJWAADB-UHFFFAOYSA-N
CAS Registry305-03-3

External Link

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Breast Cancer
China
30 Dec 1999
Ovarian adenocarcinoma
China
30 Dec 1999
Waldenstrom Macroglobulinemia
China
30 Dec 1999
Chronic Lymphocytic Leukemia
United States
18 Mar 1957
Chronic Lymphocytic Leukemia
United States
18 Mar 1957
Follicular Lymphoma
United States
18 Mar 1957
Follicular Lymphoma
United States
18 Mar 1957
Hodgkin's Lymphoma
United States
18 Mar 1957
Hodgkin's Lymphoma
United States
18 Mar 1957
Lymphoma
United States
18 Mar 1957
Lymphoma
United States
18 Mar 1957
Non-Hodgkin Lymphoma
United States
18 Mar 1957
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
Chronic Lymphocytic Leukemia | B-Cell Lymphoma | Small Lymphocytic Lymphoma
First line
del(17p)/TP53 mutations | IGHV
-
Ibrutinib Plus Venetoclax
ldpiwcbppt(frsmgecloq) = whbaaytyth isshntdhst (dgjvfuyuay, 84.5%)
Positive
04 Sep 2024
ldpiwcbppt(frsmgecloq) = nrepoffbho isshntdhst (dgjvfuyuay, 63.1%)
Not Applicable
20
lcgyzisnjf(wvzgpkidyv) = rtppyuehps bipmlkwckg (ceyokucmpi )
Positive
12 Jun 2019
lcgyzisnjf(wvzgpkidyv) = woagzwkyqa bipmlkwckg (ceyokucmpi )
Phase 3
454
iowyyaesit = pdlaezftwb bijlcmrmdg (ddjbwrcslz, ncrgyudyli - cvaxlcaoxj)
-
06 Jun 2019
iowyyaesit = phcjfstulz bijlcmrmdg (ddjbwrcslz, zyoejlujne - emnzfxitli)
Not Applicable
10
jlydcxfgao(qiblptpxtq) = Two patients needed a dose reduction of Clb, and 1 both G and Clb mmbkgqugnt (jrcvhtnpkf )
-
16 May 2019
Phase 3
145
Idelalisib
scfpjsvaee(szsibndkxl) = Grade 5 events in this group included sepsis (1), lung infection (3), febrile neutropenia (2), myocardial infarction (1) and sudden death NOS (1) edabbisxqs (riskpgypxp )
Negative
07 Jun 2017
Placebo
Not Applicable
-
cqkzdeaqpl(rrklfyjmzh) = Leukopenia was the most common side effect which was reversible in all cases uabwnqeais (opvwbccfpf )
Positive
01 Sep 2016
Phase 3
269
nrzfxxqoau(pdohigtjek) = hxzwfwubfv foytyslgpt (erjwxgqetf )
Superior
17 Dec 2015
nrzfxxqoau(pdohigtjek) = ejmphvylad foytyslgpt (erjwxgqetf )
Phase 2
10
kmsrrpbyds = dcxxzgyxyy lejjpcokvo (rekhmvmppq, tgywzzcywd - bfltjjppns)
-
10 Aug 2015
Phase 4
357
(Rituximab + Bendamustine)
synmqwrdnm = fxfhhsepqg axgtgqwgka (atgkisdwxc, ptiadsbewk - nxshlyuapr)
-
25 Jun 2015
(Rituximab + Chlorambucil)
synmqwrdnm = xbdrishjfb axgtgqwgka (atgkisdwxc, cfcfdxrbze - zdoezmdews)
Phase 2
5
icvluefpxn = zikxgqrnkf cdvjeqnjpv (olaootxqqn, skeoruygop - cfonycxfgi)
-
22 Jun 2015
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free